As of May 25th, we have reopened our office in Kyiv as the situation in the Ukrainian capital stabilises. The reopening is on a voluntary basis for employees and we are continuously reviewing the situation to ensure their safety.
Our products remain available in approximately 80% of Ukraine. For healthcare professionals and patients, we continue to support questions about product availability through our dedicated hotline (see below).
We have established a hotline for patients and healthcare providers in Ukraine to inform about the availability of our products. We will do our best to provide all necessary information.
As a pharmaceutical company, it is our responsibility to supply essential medicine to patients with chronic diseases, and we will do all we can to maintain supply in Ukraine and Russia.
With normal supply chains disrupted, we are in dialogue with several international humanitarian organisations to provide relief and have donated medicines and supplies to the Ukrainian Ministry of Health.
We are doing all we can to maintain the supply of essential medicines to patients living with chronic diseases in Ukraine.
We have donated up to two months' supply of life-saving medicine for diabetes and haemophilia from our current stock in Ukraine to the Ministry of Health.
Additionally, the Novo Nordisk Foundation has donated 80 million Danish kroner (approx 10.7m Euro) to support the work of international relief organisations in receiving and assisting refugees, internally displaced people and other vulnerable groups with access to basic necessities such as food and shelter, health and protection
We are in dialogue with several international humanitarian organisations to assess need for product donations. We are looking into different ways we can positively contribute including through our own supply chain capacity and expertise.
For details, see Frequently Asked Questions below - What is Novo Nordisk doing to support patients in Ukraine that need access to medicines?
Your Career Guide